Nuance Communications Inc.  announced in November that it enhanced its PowerShare Network capabilities in collaboration with Coordinated Care of Oklahoma (CCO) to make image awareness in health information exchanges (HIEs) now a reality. CCO is a leading health information network of hospitals, health systems and physicians in Oklahoma.

Mirada Medical showcased its latest XD:PACS (picture archiving and communication system) range of molecular imaging products at the 2016 Radiological Society of North America (RSNA) annual meeting, Nov. 27-Dec. 1 in Chicago.

In nuclear medicine, the goal is to keep radiation exposure at a minimum, while obtaining quality images. Optimal dosing for individual patients can be difficult to determine. That’s where 3-D-printed organ models of varying size and shape could be of great use.

Image Information Systems released version 3.0 of its iQ-VIEW radiology reading station in November and displayed it at the 2016 annual meeting of the Radiological Society of North America (RSNA) in Chicago.

SyntheticMR AB introduced REMyDI for automatic quantification of myelin volume in the brain at the 2016 annual meeting of the Radiological Society of North America (RSNA) in November. Easy quantification of myelin allows clinicians to follow myelination in the developing brain and monitor myelin degeneration in patients with demyelinating and neurodegenerative disorders. REMyDI is a feature of the SyMRI post-processing software from SyntheticMR.

New research demonstrates that a novel imaging agent can quickly and accurately detect metastasis of prostate cancer, even in areas where detection has previously been difficult. Published in the December issue of The Journal of Nuclear Medicine, the Phase 1 dose-escalation study of Zr-89-desferrioxamine-IAB2M (Zr-89-Df-IAB2M), an anti-PSMA (prostate-specific membrane antigen) minibody, in patients with metastatic prostate cancer shows its effectiveness in targeting both bone and soft tissue lesions.

Toshiba Medical announced in November that its Vantage Titan 1.5T/cS Edition magnetic resonance imaging (MRI) system with M-Power V3.6 software received U.S. Food and Drug Administration (FDA) clearance at the 2016 annual meeting of the Radiological Society of North America (RSNA). The new system retains all the patient-friendly features of the Vantage Titan 1.5T MR with added technology to simplify complex cardiac exams.

Vantage Titan 1.5T cS Edition

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now